Comparison between the AroCell TK 210 ELISA and TK1 enzyme activity assays

AroCell recently completed a comparison between their 210 ELISA with the ABCAM TK1 ELISA and the Gold-Standard Tritiated TK1 Activity Assay to confirm the diagnostic accuracy of each kit. The results found that the AroCell kit is an accurate assay for the determination of thymidine kinase 1.

Read the report here.

Eagle Biosciences offers the AroCell TK 210 ELISA as part of our product catalog:
TK 210 (Thymidine Kinase 1 (TK1)) ELISA Assay Kit

Contact us for more information about this or other enzyme activity assays.

Join Us for a Special Webinar Featuring the New TK 210 ELISA Assay Kit

Wednesday, November 15, 2017 at 10:00 AM EST



AroCell TK 210 ELISA:

A Novel Proliferation Biomarker to 

Study Hematological Malignancies

Thymidine Kinase 1 (TK1) has been long known as a valuable biomarker of cellular proliferation. However, previous methods have been based on enzyme activity measurements that are complex and require specialized equipment. Introducing the AroCell TK 210 ELISA as a new valuable assay for TK1 that brings the simplicity and robustness in a widely available assay kit (sold only in the US by Eagle Biosciences). Based on unique monoclonal antibodies (TK 210 epitope), the AroCell TK 210 ELISA Assay Kit creates an easy to use assay and provides new opportunities for studying cellular proliferation, tumor cell turnover and therapy response in subjects with hematological malignancies. 

During this webinar, you will learn the importance of proliferation biomarkers, and their key role in monitoring malignancies, as well as the aiding in making prognoses which could provide early insights into the effects of therapy. Since Thymidine kinase 1 (TK1) is a well-known proliferation biomarker, studying this biomarker has been based on enzyme activity methods and may underestimate serum TK1 levels, particularly in subjects with solid tumors. Improved immunoassays of TK1 based on the TK 210 antigen (AroCell TK 210 ELISA) has shown promising insight of studying these hematological malignancies. 


Meet the Speakers: 

Staffan Eriksson | Professor in Medical and Physilogical Chemistry at the

Swedish University of Agricultural Sciences

Steffan Eriksson has been active in the research of medical biochemistry and Thymidine Kinase for many decades, and has published over 120 scientific studies related to these topics. He is also founder of AroCell AB and one of the inventors of the TK 210 ELISA Assay test for measuring cell grown and turnover. 


Martin Shaw | AroCell Development Manager

Martin Shaw has had a long experience in the development and application of many novel biomarkers. He has participated in industry-wide consortia on the qualification of biomarkers for application in pre-clinical and clinical trials. He has spoken at many congresses including being a guest speaker at the FDA. 


We Hope You Can Join Us!



If you would like to receive a white paper on the use of TK1 and TK 210
ELISA in studying hematological malignancies, please 
click here


Eagle Biosciences and AroCell are pleased to invite you to a
webinar on the application of the TK
210 (Thymidine Kinase 1) ELISA
in the study of malignancies.

There are many biomarkers of tumor mass, but few serum
biomarkers of tumor proliferation, a key indicator when making prognoses
and choosing and monitoring therapy.

The assay of serum Thymidine Kinase 1 with the AroCell TK 210
ELISA has the potential to be such a biomarker. There is no cost for
this event.


When: March
23, 2017 | 11 am to 11:30 am EDT


  • Staffan Eriksson, Professor in Medical and Physiological Chemistry, Swedish
    University of Agricultural Sciences
  • Martin
    , Business Development Manager at AroCell.

Key points of the presentation will be:

  • Thymidine
    kinase 1 (TK1) is a well-known proliferation biomarker but most
    current methods are based on enzyme activity methods and may
    underestimate serum TK1 levels, particularly in subjects with solid
  • The AroCell
    TK 210 ELISA adds value to studies with existing tumor biomarkers
  • Data will be
    presented on the value of the AroCell TK 210 ELISA in the study of a
    range of hematological and solid tumors.

Receive a white paper on the use of TK1 and the AroCell TK210 ELISA in studying solid tumors HERE



About AroCell

AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.


, manufactured by AroCell is offered in EagleBio’s Cancer Biomarker Assay Line. The Cancer
Biomarker Assay Kit Line offered Eagle Biosciences provides a comprehensive
array of sensitive and valuable tools to assist researchers in new emerging
market segments in cancer research such as tumor marker and anti-tumor therapy

Our TK
is a convenient, simple test as well as the most sensitive
ELISA for measuring TK1.

Why Measure Thymidine Kinase 1 (TK1)?

The enzyme Thymidine Kinase 1 (TK1) is up-regulated in
tumor cells from which it is released into the blood during their turnover.
Increased serum TK1 protein has been discovered to be associated with tumor
growth. TK1 up-regulation may be an early event in cancer development and TK1
may even be elevated in pre-cancerous conditions.1

Although TK1 activity is a valuable biomarker it has
limitations in that most current methods are based on enzyme activity
assays.The AroCell TK 210 ELISA test, based on two monoclonal antibodies
specific for a unique TK1 amino acid sequence (194-225), brings the
specificity, sensitivity and robustness of immunoassay to the assay of serum

Key Advantages of TK 210 ELISA:

  • Most
    Sensitive ELISA for measuring TK1
  • Simple
    ELISA procedure with same day results
  • Accurately
    measure both Active & Inactive TK1
  • Solid
    tumors do not affect results unlike other methods for measuring TK1
  • Strong
    Evidence that TK210 can be used successfully with traditional cancer
    markers like CA15-3
  • Use
    with both Serum or Tissue samples

Recent Citations:

Publications List



M.M. et al. (2012). Thymidine Kinase 1 Upregulation Is an Early Event in Breast
Tumor Formation. Journal of Oncology. Volume 2012, 5 pages.

J.K. et al. (2016). A Clinical Evaluation of the TK 210 ELISA in Sera from
Breast Cancer Patients Demonstrates High Sensitivity and Specificity at All
Stages of the Disease. Tumor Biology. DOI 10.1007/s13277-016-5024-z (Epub ahead
of print)

Introducing the TK 210 ELISA assay kit from AroCell, the most sensitive assay available for measuring Thymadine Kinase 1 (TK1). TK1 is a key enzyme in DNA replication and it is up-regulated in proliferating cells. Many studies have shown it to be a valuable cancer biomarker but most previous assays have been activity based and underestimate TK1 in solid tumors.&nbspRead More


TK 210 ELISA is for Research Use Only. Not for Use in Diagnostic Procedures in the US.